ArticleProceedings of the National Academy of Sciences of the United States of America2023
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
16.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC.Cancer science · 2026Article
- Mechanisms of inflammatory response in secondary brain injury: a review of computational approaches, challenges, and future directions.Biomechanics and modeling in mechanobiology · 2026Review
- Microenvironmental regulation of solid tumour resistance to CAR T cell therapy.Nature reviews. Immunology · 2026Review
- Review
- Mechanical compression induces neuronal apoptosis, reduces synaptic activity, and promotes glial neuroinflammation in mice and humans.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Losartan Alleviates Chemical Burn-Induced Limbal Stem Cell Deficiency: Repurposing a Venerable Anti-Hypertension Drug.Investigative ophthalmology & visual science · 2026Article
- Current Status of Research on Losartan in Tumour Therapy.Journal of cellular and molecular medicine · 2026Review
- Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application.Cancer research and treatment · 2026Review
- Review
- Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells.Scientific reports · 2025Article
- Pan-cancer and machine learning reveal the role of cell adhesion molecules in prognosis, immune remodeling, and anti-tumour therapy in lower-grade gliomas.Discover oncology · 2025Article
- New experimental therapies for glioblastoma: a review of preclinical research.Acta neuropathologica communications · 2025Review
- Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- Probing the physical hallmarks of cancer.Nature methods · 2025Review
- Targeting cancer cell stiffness and metastasis with clinical therapeutics.Clinical & experimental metastasis · 2025Review
- Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy.JTO clinical and research reports · 2025Article
- Gut-Brain-Microbiome Axis in the Regulation of Cancer Immune Escape and Immunotherapy in Tumors.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 2 countries.
Meenal DattaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-5727-8992
Sampurna ChatterjeeEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Elizabeth M PerezDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Simon GritschDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Sylvie RobergeEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Mark DuquetteEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Ivy X ChenEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Kamila NaxerovaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-7744-5110
Ashwin S KumarEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0003-3251-9977
Mitrajit GhoshEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Kyrre E EmblemDepartment of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, 0372 Norway.
Mei R NgEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
William W HoEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0002-1272-8184
Pragya KumarEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Shanmugarajan KrishnanEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Xinyue DongEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Maria C SperanzaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
Martha R NeaguDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.
J Bryan IorgulescuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.ORCID 0000-0003-1405-3667
Raymond Y HuangDepartment of Radiology, Brigham and Women's Hospital, Boston, MA 02115.
Gilbert YoussefCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
David A ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
Arlene H SharpeBroad Institute of MIT and Harvard, Cambridge, MA 02142.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.ORCID 0000-0002-7210-5616
Mario L SuvàDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-9898-5351
Lei XuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-7571-3548
Harvard University · USBroad Institute · USBrigham and Women's Hospital · USCenter for Neuro-Oncology · USDana-Farber Cancer Institute · USOslo University Hospital · NO
Funding
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5MUnderstanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca · 2020 to 2026
$19.5MDissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MTargeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1MReprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9MDissecting the cellular hierarchies of malignant gliomas by single-cell functional genomicsR37CA245523 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Mario Luca Suva · 2020 to 2026
$2.8MDeciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omicsR01CA258763 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SUVA, MARIO LUCA · 2021 to 2025
$2.8MImproving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3MReengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2MReprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0MReprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9MEstablishing an immune mechanomeR35GM151041 · NIGMS · UNIVERSITY OF NOTRE DAME · PI Meenal Datta · 2023 to 2026
$1.7MNCI NIH HHS K22 CA258410NCI NIH HHS P01 CA236749NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA258763NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA269672NCI NIH HHS R35 CA197743NCI NIH HHS R37 CA245523NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NIAID NIH HHS P01 AI056299NIGMS NIH HHS R35 GM151041NINDS NIH HHS R01 NS118929
Abstract
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and CD8
Indexed as
GlioblastomaAnimalsCD8-Positive T-LymphocytesEdemaImmune Checkpoint InhibitorsLosartanMiceTumor MicroenvironmentImmune Checkpoint InhibitorsLosartanbiomarkersglioblastomaimmune checkpoint blockersimmune-related adverse eventstumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.